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Background: Recurrent optic neuritis (rON) associated with
myelin oligodendrocyte glycoprotein (MOG)-speciﬁc antibod-
ies has been initially reported to show a better clinical
outcome than aquaporin-4 (AQP4)-seropositive ON in neu-
romyelitis optica spectrum disorder (NMOSD). Here, we
characterize clinical and neuroimaging ﬁndings in severe
cases of MOG antibody–positive and AQP4 antibody–
negative bilateral rON.
Methods: Three male adults with rON (ages 18, 44, and 63
years) were evaluated with optical coherence tomography
(OCT), MRI, cerebrospinal ﬂuid (CSF), and serological
studies.
Results: All patients experienced .7 relapses of ON with
severe reduction of visual acuity and partial response to
steroid treatment. Optic nerves were affected bilaterally,
although unilateral relapses were more frequent than simul-
taneous bilateral recurrences. Patients were MOG-
seropositive but repeatedly tested negative for AQP4
antibodies. OCT showed severe thinning of the peripapillary
retinal nerve ﬁber layer. On MRI, contrast-enhancing lesions
extended over more than half the length of the optic nerve.
CSF analyses during ON episodes were normal. Severe
visual deﬁcits accumulated over time in 2 of 3 patients,
despite immunosuppressive therapy.
Conclusions: MOG-seropositive and AQP4-seronegative rON
may be associated with an aggressive disease course and
poor functional and structural outcomes. In contrast to
previous reports, the severity and pattern of retinal and
optic nerve damage closely resembled phenotypes com-
monly observed in AQP4-seropositive rON without fulﬁlling
current diagnostic criteria for NMOSD.
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M yelin oligodendrocyte glycoprotein (MOG)-speciﬁcantibodies have been detected in peripheral blood of
pediatric patients with acute disseminated encephalomyelitis
(ADEM), but also in adults with benign, unilateral cerebral
cortical encephalitis, aquaporin-4 (AQP4)-seronegative neu-
romyelitis optica spectrum disorder (NMOSD), AQP4-
seronegative brainstem encephalitis, AQP4-seronegative
(often longitudinally extensive) transverse myelitis, or in sub-
jects with AQP4-seronegative optic neuritis (ON) (1–7).
Because classic NMOSD is considered an astrocytopathy,
and MOG antibody–associated diseases primarily display
demyelination in the central nervous system, it has been
a matter of debate whether MOG-seropositive, AQP4-
seronegative syndromes should be classiﬁed as NMOSD, or
whether they rather represent a separate autoimmune disease
entity (8,9). MOG-seropositivity has been reported to be
more frequently associated with simultaneous bilateral ON,
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a monophasic disease course and a better functional outcome
as compared to AQP4-seropositivity (10–14). Only recently
have severe MOG antibody–associated recurrent ON (rON)
been described (5,9,15,16). We evaluated 3 adult male pa-
tients with severe MOG antibody–positive rON and our
aggressive immunosuppressive treatment attempts that could
not prevent signiﬁcant structural and/or functional sequelae.
METHODS
Patients provided written informed consent according to
Swiss legislation; the use of clinical data was approved by
the Cantonal Ethical Committee of Zurich, Switzerland
(EC-ZH-No. 2013-0001). All patients received MRI and
cerebrospinal ﬂuid (CSF) examinations as routine diagnos-
tic workup. Mean peripapillary retinal nerve ﬁber layer
(pRNFL) thickness and macular volumes were assessed by
optical coherence tomography (OCT) using a Spectralis
SD-OCT device (Heidelberg Engineering, Heidelberg,
Germany). Visual acuity (VA) was measured using Snellen
charts; high- and low-contrast VA were assessed using
ETDRS-style and 2.5% contrast SLOAN charts, respec-
tively. Serum anti-MOG and anti-AQP4 antibodies were
measured at the Clinical Department of Neurology, Inns-
bruck Medical University, by a cell-based assay as previously
described (3). All patients were diagnosed with MOG-
associated rON after excluding other diagnoses.
CASE REPORTS
Patient 1
A 18-year-old man experienced ON with subacute, painful
visual loss in his right eye to hand movements. After high-
dose corticosteroid, acuity in the right eye improved to 20/
200. One month after the onset of ON, he experienced
focal motor sensory and secondary generalized seizures. CSF
analysis revealed normal cell count and protein levels
without oligoclonal bands (OCBs). Brain MRI showed
contrast enhancement over half the lengths of both optic
nerves and the optic chiasm, as well as multiple T2- and
contrast-enhancing lesions in the corpus callosum. Epileptic
seizures subsided when the patient was treated with
levetiracetam. Over the next 4 months, he experienced an
episode of chiasmitis and 3 episodes of left ON. Treatments
included high-dose corticosteroids and plasma exchange on
5 occasions.
Six months after his initial episodes of visual loss, he was
referred to our institution. VA was 20/125, right eye, and
worse than 20/400, left eye. pRNFL thickness was reduced
in both eyes (right 46 mm and left 84 mm), with preferen-
tial thinning of the papillomacular bundle and the nasal and
temporal quadrants (see Supplemental Digital Content 2,
Fig. E1, http://links.lww.com/WNO/A308). Sera obtained
on 3 occasions over a span of 10 months revealed MOG
antibodies with titers ranging from 1:160 to 1:640. AQP4-
antibody tests were repeatedly negative. MOG antibody–
associated chronic relapsing inﬂammatory optic neuropathy
(CRION) was diagnosed.
Over the 6 months after our initial evaluation, the
patient experienced 1 episode of right ON and 2 of left
ON, despite continuous treatment with oral steroids (5–
100 mg/day), use of rituximab 2 · 375 mg/m2, and plasma
exchange. Notably, these episodes occurred during tapering
the dose of steroids, and each responded moderately to
high-dose oral steroids (100 mg/day over 5 days). Nine
months after his initial episode, MRI showed persistent
contrast enhancement of both optic nerves.
During the next 7 months, mycophenolate mofetil (up to
3,000 mg/day) was added as additional therapy. MRI no
longer showed optic nerve enhancement. After repeating
rituximab (1 · 375 mg/m2), disease activity stabilized. At last
follow-up, VA was 20/200, right eye, and no light percep-
tion, left eye, with pRNFL thickness of 28 mm in each eye.
In summary, 5 of 9 ON events were not only severe, but
led to severe residual visual deﬁcits. Rituximab therapy reduced
relapse frequency, but could not prevent legal blindness (acuity
worse than 20/200) as ﬁnal outcome. The addition of
mycophenolate mofetil to rituximab ameliorated the visual
deﬁcit on the right eye over time (see Supplemental Digital
Content 1, Table E1, http://links.lww.com/WNO/A307).
Patient 2
A 43-year-old man was referred with an 8-year history of
severe, painful rON. He initially experienced right ON with
MRI showing edema and contrast enhancement along the
entire right optic nerve. CSF analysis was normal. Sub-
sequently, he had 1 additional episode of right ON, 4 of left
ON, and 1 episode occurred bilaterally resulting in legal
blindness. Although VA during ON episodes was reduced
to as low as ﬁnger counting on both sides, the patient
initially responded well to high-dose corticosteroid treat-
ment. Therapy with azathioprine over 6 months was
unsuccessful in preventing ON relapses. Repeat MRIs over
5 years showed exclusive optic nerve enhancement, whereas
the spinal cord seemed normal. Multiple CSF analyses were
normal. A diagnosis of CRION was made.
On our examination, VA was 20/20, right eye, and 20/
32, left eye. OCT revealed pRNFL thinning (right:
48 mm; left: 52 mm) (See Supplemental Digital Content
2, Fig. E1, http://links.lww.com/WNO/A308). The
patient ultimately stabilized, after rituximab (375 mg/
m2) was given (See Supplemental Digital Content 1,
Table E1, http://links.lww.com/WNO/A307). Most
recently, acuity was 20/16 in both eyes. On 2 occasions,
serum tested positive for MOG antibodies (titers 1:1,280
and 1:2,560) and negative for AQP4 antibodies.
Generally, Patient 2 recovered well after each of 10 ON
events including severely disabling events. Rituximab
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treatment reduced relapse frequency and may have stabi-
lized the disease course in this patient.
Patient 3
A 59-year-old man experienced subacute back pain, urinary
retention, saccadic smooth pursuit, and fever 6 weeks after
an inﬂuenza vaccination. CSF analysis revealed an elevated
cell count (183/mL) without OCB. MRI showed multiple
T2-hyperintense bilateral thalamic, mesencephalic, pontine,
and cervical, thoracic and lumbar spinal lesions with con-
trast enhancement of the thalamic, mesencephalic, pontine,
and thoracic lesions. Microbiology and virology testing was
negative, as was screening for AQP4 antibodies. A diagnosis
of ADEM was made.
Two months later, he experienced painful right ON,
with VA of 20/40. MRI demonstrated edema and contrast
enhancement of almost the entire length of the right optic
nerve. He was treated with high-dose corticosteroids, yet
suffered a relapse of painful right ON. One month later,
natalizumab (300 mg monthly) was added to the treatment
regimen, but 3 further relapses of painful right ON
occurred within 2 months. With a combination of
intravenous high-dose steroids and plasma exchange, VA
recovered to 20/40 in the right eye. Two months later, he
received rituximab (375 mg/m2), and 1 month later,
another 1000 mg.
Nevertheless, 2 months after the last rituximab infusion,
he developed painful left ON and was given monthly
infusions of cyclophosphamide (600–1100 mg/m2/cycle)
for 13 months. During that time, the patient had 2 addi-
tional episodes of right ON. Repeat CSF analysis was unre-
markable. Monthly infusions of tocilizumab (8 mg/kg) led
to 17 months without relapse. VA was light perception,
right eye, and 20/25, left eye. Measurement of pRNFL
thickness was 30 mm, right eye, with thinning over all
quadrants (See Supplemental Digital Content 2, Fig E1,
http://links.lww.com/WNO/A308), and 62 mm, left eye,
with predominant thinning over the nasal and inferior
quadrants. MRI demonstrated atrophy of the right optic
nerve and multiple supratentorial, T2-hyperintense lesions,
but resolution of all spinal cord lesions. MOG antibodies
were detected at a titer of 1:160 on 2 occasions but negative
for AQP4 antibodies.
In summary, 4 of 8 ON events were severe and led to
disabling residual visual deﬁcits. Rituximab and cyclophospha-
mide treatment, respectively, reduced relapse frequency, but could
not prevent severe ON relapses. Only initiation of tocilizumab
therapy stabilized the disease completely without any further
relapses or visual deterioration (See Supplemental Digital Con-
tent 1, Table E1, http://links.lww.com/WNO/A307).
DISCUSSION
We present 3 adult male patients with MOG antibody–
associated rON (MOG-ON) with poor structural out-
comes in all cases and poor functional outcomes in 2 of 3
cases. None of our patients fulﬁlled current diagnostic cri-
teria for NMOSD (17). Two patients experienced an
ADEM-like episode after (Patient 1) or before (Patient 3)
their ﬁrst episode of ON. In accordance with previous re-
ports (16,18), CSF ﬁndings were normal in 2 patients dur-
ing MOG-ON episodes. The initial elevated CSF cell count
and mild blood–brain barrier dysfunction in Patient 3 may
be related to the antecedent inﬂuenza vaccination and
suggestive of both MOG-seropositive ADEM and
NMOSD, as both have been reported to feature increased
CSF cell counts (12,19). To the best of our knowledge, this
is only the third case with vaccination-related MOG-sero-
positive disease (9). Other MOG-seropositive cases have
been associated with viral or bacterial infection including
inﬂuenza virus infection, Epstein–Barr virus-induced infec-
tious mononucleosis and Chlamydia pneumoniae infection
(20–22). In these cases, autoreactive MOG antibody–
producing B cells may be activated by both the simulta-
neous uptake of the cognate autoantigen (MOG) and the
“bystander” viral antigen (e.g., inﬂuenza hemagglutinin)
into B cells from infected parenchymal cells and by T cells
speciﬁc for the respective antigen (23).
Extensive contrast enhancement of the optic nerve
(frequently extending over more than half of the entire
length and involving the chiasm) on MRI and marked
thinning of the entire pRNFL resembled typical ﬁndings in
NMOSD (24). OCT studies have shown preferential tem-
poral pRNFL thinning in multiple sclerosis–associated
rON, whereas the initial involvement of the superior and
inferior quadrants is typical in NMOSD-associated rON
along with severe macular thinning (24,25). By contrast,
in all 3 patients with MOG-ON reported here, pRNFL
thickness was reduced in all quadrants.
Tapering of corticosteroid therapy led to ON relapses in
Patient 1. Dependency on long-term corticosteroid treat-
ment and good responsiveness to high-dose corticosteroid
treatment are typical of CRION. MOG-seropositive
CRION and rON cases with rapid steroid response and
increased relapse risk after steroid cessation have been
reported (4,9,16). Notably, Patients 1 and 2 showed only
partial clinical response to antibody-targeted therapy with
rituximab.
Within the past few years, the ﬁrst MOG-ON cases with
the onset of .18 years of age have been reported (15,16).
These patients tended to show worse VA outcome than
pediatric cases (15). However, only 2 of 14 patients in these
reports (Case 10 (15); Case 7 (16)) experienced such a severe
reduction of VA like the cases presented here. Subsequently,
other cases with recurrent (14,27) and/or severe disease
course have been described (9,28,29). As reports of
MOG-seropositive patients with longer follow-up (.5
years) become available, poor visual outcomes will likely
become more prevalent.
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Because MOG-ON reportedly affects female patients
more often than male patients, with higher annualized
relapse rate in female patients (9), the cases reported here
(all men and frequent rON) may represent one end of the
spectrum of MOG-ON. Whether the later onset of MOG-
ON and/or gender of the individual is associated with
a more aggressive disease course warrants further study.
Testing for MOG antibodies should be considered in cases
of rON or suspected NMOSD, particularly in patients with
AQP4-seronegative. Notably, MOG antibody titers did not
relate to ON severity or pRNFL loss. Future studies includ-
ing larger case series will have to address the pathological
relevance and overall clinical utility of MOG-antibody test-
ing for clinical decision making.
In summary, our cases suggest that MOG-ON may be
associated with disabling structural and functional visual
outcomes, similar to patients with AQP4-seropositive ON.
Initiation of high efﬁcacy immune therapy should be
evaluated early in these patients, especially when initial
episodes are followed by poor visual outcome.
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